Yuko Yoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuko Yoto has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Tsutsumi
Department of Pediatrics Sapporo Medical University School of Medicine Sapporo Japan
11 shared publications Aki Ishikawa
Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan
6 shared publicationsHiroyuki Tsutsumi
Department of Pediatrics Sapporo Medical University School of Medicine Sapporo Japan
6 shared publicationsNaoki Hatakeyama
Department of Pediatrics, Asahikawa Medical University Hospital, Asahikawa, Japan
4 shared publicationsTsukasa Hori
Department of Pediatrics, Center for Medical Education, Sapporo Medical University School of Medicine, Sapporo, Japan
4 shared publicationsHiroshi Ikeda
Department of Hematology, Center for Medical Education, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications
Latest Publications
- 5 September 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (9) , 882-884
Anemia associated with increased hepcidin in two children with Castleman disease
- 5 September 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (9) , 882-884
Anemia associated with increased hepcidin in two children with Castleman disease
- 14 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (6) , 547-552
Long‐term prognosis of human herpesvirus 6 reactivation following allogeneic hematopoietic stem cell transplantation
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) frequently have HHV‐6 reactivation typically during the early phase following HSCT. The long‐term clinical complications and prognosis, however, remain unclear.Methods: Between September 2010 and October 2012, whole blood samples from 105 patients collected weekly from prior to 6 weeks after HSCT underwent multiplex polymerase chain reaction (PCR) to screen for viral DNA, followed by real‐time PCR for quantitative estimation. In 48 patients, only HHV‐6 was detected in at least one sample. In 30 patients, no viral DNA was detected. Long‐term clinical records were reviewed in March 2016. All 48 HHV‐6‐positive patients, and 24 patients in whom no viral DNA detected, were followed up.Results: Median maximum HHV‐6 DNA load in the blood of the HHV‐6 reactivation group (n = 48) was 11 800 copies/μg peripheral blood leukocyte DNA (range, 52–310 000 000). Hemophagocytic syndrome (HPS) was diagnosed in two subjects with HHV‐6 reactivation. Acute graft‐versus‐host disease (GVHD) developed more frequently in patients with HHV‐6 reactivation than in patients without viral reactivation (P = 0.002), but there was no difference in incidence of chronic GVHD. There was no difference in engraftment of neutrophils and platelets between groups. There was also no difference in overall survival between groups. Onset of HPS, however, was associated with lower overall survival (P = 0.009).Conclusions: Human herpesvirus 6 reactivation was associated with acute GVHD, but not with chronic GVHD, engraftment or overall survival. Onset of HPS, however, predicts lower overall survival.
- 14 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (6) , 547-552
Long‐term prognosis of human herpesvirus 6 reactivation following allogeneic hematopoietic stem cell transplantation
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) frequently have HHV‐6 reactivation typically during the early phase following HSCT. The long‐term clinical complications and prognosis, however, remain unclear.Methods: Between September 2010 and October 2012, whole blood samples from 105 patients collected weekly from prior to 6 weeks after HSCT underwent multiplex polymerase chain reaction (PCR) to screen for viral DNA, followed by real‐time PCR for quantitative estimation. In 48 patients, only HHV‐6 was detected in at least one sample. In 30 patients, no viral DNA was detected. Long‐term clinical records were reviewed in March 2016. All 48 HHV‐6‐positive patients, and 24 patients in whom no viral DNA detected, were followed up.Results: Median maximum HHV‐6 DNA load in the blood of the HHV‐6 reactivation group (n = 48) was 11 800 copies/μg peripheral blood leukocyte DNA (range, 52–310 000 000). Hemophagocytic syndrome (HPS) was diagnosed in two subjects with HHV‐6 reactivation. Acute graft‐versus‐host disease (GVHD) developed more frequently in patients with HHV‐6 reactivation than in patients without viral reactivation (P = 0.002), but there was no difference in incidence of chronic GVHD. There was no difference in engraftment of neutrophils and platelets between groups. There was also no difference in overall survival between groups. Onset of HPS, however, was associated with lower overall survival (P = 0.009).Conclusions: Human herpesvirus 6 reactivation was associated with acute GVHD, but not with chronic GVHD, engraftment or overall survival. Onset of HPS, however, predicts lower overall survival.
- 2 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (4) , 357-361
Predictive factors of response toIVIGin pediatric immune thrombocytopenic purpura
Background: Immune thrombocytopenic purpura (ITP) is commonly treated with i.v. immunoglobulin (IVIG).Methods: We retrospectively evaluated whether pretreatment clinical and laboratory finding could predict the short‐ and long‐term response toIVIG.Results: Short‐term response was estimated by platelet count 2 weeks afterIVIG, and long‐term response was assessed on thrombocytopenia‐free survival (TFS).TFSwas defined as the probability of survival without treatment failure after initialIVIG, such as relapse, requirement for additional therapeutic interventions, or progressing to chronicITP. Seventy‐six patients with newly diagnosedITPwho were initially treated withIVIGwere evaluated. Fifty‐three patients (69.7%) were determined as responders at 2 weeks afterIVIG. On multivariate analysis, age ≥23 months (P= 0.020) and platelet count 9/L (P= 0.018) were considered to be unfavorable factors for short‐term response. Cumulative proportion of long‐term (1 year) good prognosis was estimated at 53.0% (95%CI: 40.8–65.2). On multivariate analysis of unfavorable factors for long‐term response, age ≥23 months (P= 0.020) was the only significant factor.Conclusions: For new‐onsetITPin patients aged >2 years, corticosteroid therapy in addition toIVIGmay be considered as the initial treatment.
- 2 March 2018
- Published by Wiley in Pediatrics International
- Vol. 60 (4) , 357-361
Predictive factors of response toIVIGin pediatric immune thrombocytopenic purpura
Background: Immune thrombocytopenic purpura (ITP) is commonly treated with i.v. immunoglobulin (IVIG).Methods: We retrospectively evaluated whether pretreatment clinical and laboratory finding could predict the short‐ and long‐term response toIVIG.Results: Short‐term response was estimated by platelet count 2 weeks afterIVIG, and long‐term response was assessed on thrombocytopenia‐free survival (TFS).TFSwas defined as the probability of survival without treatment failure after initialIVIG, such as relapse, requirement for additional therapeutic interventions, or progressing to chronicITP. Seventy‐six patients with newly diagnosedITPwho were initially treated withIVIGwere evaluated. Fifty‐three patients (69.7%) were determined as responders at 2 weeks afterIVIG. On multivariate analysis, age ≥23 months (P= 0.020) and platelet count 9/L (P= 0.018) were considered to be unfavorable factors for short‐term response. Cumulative proportion of long‐term (1 year) good prognosis was estimated at 53.0% (95%CI: 40.8–65.2). On multivariate analysis of unfavorable factors for long‐term response, age ≥23 months (P= 0.020) was the only significant factor.Conclusions: For new‐onsetITPin patients aged >2 years, corticosteroid therapy in addition toIVIGmay be considered as the initial treatment.
- 29 October 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (10) , 1123-1125
Immunochromatography test for rapid diagnosis of Mycoplasma pneumoniae infection
The sensitivity and specificity of a new rapid Mycoplasma pneumoniae antigen immunochromatography (IC) test, DK‐MP‐001, were determined using particle agglutination (PA) antibody response and loop‐mediated isothermal amplification (LAMP) gene detection as the gold standard. Of 165 patients, 59 were diagnosed with M. pneumoniae infection based on a ≥fourfold rise of serum PA antibody during the course of the illness. Of the first visit swabs, 60 were positive for M. pneumoniae on LAMP, and 49 were positive for M. pneumoniae antigen on IC test. Compared with PA antibody and LAMP, the sensitivity/specificity of the IC test were 81.4% (48/59) and 99.1% (105/106); and 81.7% (49/60) and 100% (105/105), respectively. IC test detected antigen in pharyngeal swabs more sensitively than in nasal swabs for the same subjects (P < 0.05). The IC test performs well enough to be used with pharyngeal swabs at the first examination.
- 29 October 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (10) , 1123-1125
Immunochromatography test for rapid diagnosis of Mycoplasma pneumoniae infection
The sensitivity and specificity of a new rapid Mycoplasma pneumoniae antigen immunochromatography (IC) test, DK‐MP‐001, were determined using particle agglutination (PA) antibody response and loop‐mediated isothermal amplification (LAMP) gene detection as the gold standard. Of 165 patients, 59 were diagnosed with M. pneumoniae infection based on a ≥fourfold rise of serum PA antibody during the course of the illness. Of the first visit swabs, 60 were positive for M. pneumoniae on LAMP, and 49 were positive for M. pneumoniae antigen on IC test. Compared with PA antibody and LAMP, the sensitivity/specificity of the IC test were 81.4% (48/59) and 99.1% (105/106); and 81.7% (49/60) and 100% (105/105), respectively. IC test detected antigen in pharyngeal swabs more sensitively than in nasal swabs for the same subjects (P < 0.05). The IC test performs well enough to be used with pharyngeal swabs at the first examination.
- 1 August 2016
- Published by Elsevier in Infant Behavior and Development
- Vol. 44, 227-239
Characteristics of antigravity spontaneous movements in preterm infants up to 3 months of corrected age
- 1 August 2016
- Published by Elsevier in Infant Behavior and Development
- Vol. 44, 227-239
Characteristics of antigravity spontaneous movements in preterm infants up to 3 months of corrected age
- 28 April 2015
- Published by Wiley in Pediatrics International
- Vol. 57 (4) , 582-585
Pneumococcal vaccination reduced the risk of acute otitis media: Cohort study
Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced to Japan in 2009, and after that invasive pneumococcal disease has gradually decreased. There are few data, however, on the effectiveness of PCV7 against acute otitis media (AOM) in Japan.From 10 daycare centers in Sapporo, Japan, 614 parents participated in the survey. Each parent reported whether their child subject had received one or more doses of PCV7, and, if so, the exact dates of receiving PCV7 were verified by reviewing their maternal and child health handbooks marked by a pediatrician. AOM was diagnosed by otorhinolaryngologist or pediatrician. Cox's proportional hazard model was used for calculating the hazard ratio (HR) of AOM incidence reduced by PCV7 inoculation.Inoculation of PCV7 significantly reduced the risk of AOM (crude HR, 0.63; 95%CI: 0.50-0.79). Adjusting for potentially confounding variables reduced the risk further (adjusted HR, 0.32; 95%CI: 0.23-0.44). On stratification by subject age on 30 April 2012, PCV7 was significantly associated with a reduced risk of AOM in both infants <3 years old, and in children ≥3 years.PCV7 is effectiveness in reducing the risk of AOM both in infants <3 years old, and in young children ≥3 years in Japan.
- 28 April 2015
- Published by Wiley in Pediatrics International
- Vol. 57 (4) , 582-585
Pneumococcal vaccination reduced the risk of acute otitis media: Cohort study
Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced to Japan in 2009, and after that invasive pneumococcal disease has gradually decreased. There are few data, however, on the effectiveness of PCV7 against acute otitis media (AOM) in Japan.From 10 daycare centers in Sapporo, Japan, 614 parents participated in the survey. Each parent reported whether their child subject had received one or more doses of PCV7, and, if so, the exact dates of receiving PCV7 were verified by reviewing their maternal and child health handbooks marked by a pediatrician. AOM was diagnosed by otorhinolaryngologist or pediatrician. Cox's proportional hazard model was used for calculating the hazard ratio (HR) of AOM incidence reduced by PCV7 inoculation.Inoculation of PCV7 significantly reduced the risk of AOM (crude HR, 0.63; 95%CI: 0.50-0.79). Adjusting for potentially confounding variables reduced the risk further (adjusted HR, 0.32; 95%CI: 0.23-0.44). On stratification by subject age on 30 April 2012, PCV7 was significantly associated with a reduced risk of AOM in both infants <3 years old, and in children ≥3 years.PCV7 is effectiveness in reducing the risk of AOM both in infants <3 years old, and in young children ≥3 years in Japan.
- 21 January 2015
- Published by Wiley in Journal of Medical Virology
- Vol. 87 (4) , 683-685
Quantitative analysis of human parvovirus B19 DNA in maternal and fetal serum, and amniotic fluid during an early stage of pregnancy
Simple and accurate diagnosis of vertical transmission of human parvovirus B19 (B19V) infection remains an important issue in pregnancy. There are few reports on quantitative analysis of B19V in amniotic fluids. Quantitative estimation of B19V DNA in amniotic fluids was comparerd with those in maternal or fetal serum obtained at an early stage of pregnancy with possible mother‐to‐fetus transmission. All pregnant women contracted B19V infection between 13 to 14 weeks gestation. The B19V DNA amount in 3 maternal serum and amniotic fluid sample pairs collected between 16 to 27 weeks gestation was quantified by a real‐time polymerase chain reaction assay. Serum from 2 fetuses was included. The B19V DNA concentrations in maternal sera and amniotic fluids ranged from 104 to 105 copies/ml and from 107 to 108 copies/ml, respectively. The B19V DNA in the amniotic fluids concentration coincided with those of each fetal serum. The concentrations in amniotic fluids are 100 to 5,000 times higher than in those of maternal sera, and corresponded to the matching fetal serum. Amniotic fluids may substitute for the fetal sera in terms of quantitative estimation of fetal B19V infection at an early stage of pregnancy. J. Med. Virol. 87:683–685, 2015.
- 21 January 2015
- Published by Wiley in Journal of Medical Virology
- Vol. 87 (4) , 683-685
Quantitative analysis of human parvovirus B19 DNA in maternal and fetal serum, and amniotic fluid during an early stage of pregnancy
Simple and accurate diagnosis of vertical transmission of human parvovirus B19 (B19V) infection remains an important issue in pregnancy. There are few reports on quantitative analysis of B19V in amniotic fluids. Quantitative estimation of B19V DNA in amniotic fluids was comparerd with those in maternal or fetal serum obtained at an early stage of pregnancy with possible mother‐to‐fetus transmission. All pregnant women contracted B19V infection between 13 to 14 weeks gestation. The B19V DNA amount in 3 maternal serum and amniotic fluid sample pairs collected between 16 to 27 weeks gestation was quantified by a real‐time polymerase chain reaction assay. Serum from 2 fetuses was included. The B19V DNA concentrations in maternal sera and amniotic fluids ranged from 104 to 105 copies/ml and from 107 to 108 copies/ml, respectively. The B19V DNA in the amniotic fluids concentration coincided with those of each fetal serum. The concentrations in amniotic fluids are 100 to 5,000 times higher than in those of maternal sera, and corresponded to the matching fetal serum. Amniotic fluids may substitute for the fetal sera in terms of quantitative estimation of fetal B19V infection at an early stage of pregnancy. J. Med. Virol. 87:683–685, 2015.
- Open Access
- 1 January 2015
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 24 (4) , 185-189
An adolescent case of familial hyperparathyroidism with a germline frameshift mutation of the CDC73 gene
A 13-yr-old boy who complained of persistent nausea, vomiting and weight loss had hypercalcemia and an elevated intact PTH level. Computed tomography confirmed two tumors in the thyroid gland. The tumors were surgically removed and pathologically confirmed as parathyroid adenoma. Because his maternal aunt and grandmother both had histories of parathyroid tumors, genetic investigation was undertaken for him, and a germline frameshift mutation of the CDC73 gene was identified. CDC73 gene analysis should be done on individuals who are at risk of familial hyperparathyroidism, including those who are asymptomatic, and they should be followed for potential primary hyperparathyroidism and associated disorders including resultant parathyroid carcinoma.
- 1 January 2015
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 24 (4) , 185-189
Open AccessAn adolescent case of familial hyperparathyroidism with a germline frameshift mutation of the CDC73 gene
A 13-yr-old boy who complained of persistent nausea, vomiting and weight loss had hypercalcemia and an elevated intact PTH level. Computed tomography confirmed two tumors in the thyroid gland. The tumors were surgically removed and pathologically confirmed as parathyroid adenoma. Because his maternal aunt and grandmother both had histories of parathyroid tumors, genetic investigation was undertaken for him, and a germline frameshift mutation of the CDC73 gene was identified. CDC73 gene analysis should be done on individuals who are at risk of familial hyperparathyroidism, including those who are asymptomatic, and they should be followed for potential primary hyperparathyroidism and associated disorders including resultant parathyroid carcinoma.
- 24 June 2014
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (12) , 2102-2106
Quantitation of human parvovirus B19 DNA in erythema infectiosum and aplastic crisis
Several publications concerning the methods of real-time PCR for human parvovirus B19 (B19V) have appeared and some case reports mention B19V DNA loads. However, no large-scale study quantitating levels of B19V DNA in common or representative B19V manifestations such as erythema infectiosum and aplastic crisis has been performed. Consequently, using the TaqMan PCR assay, the B19V load in a large sample of subjects with erythema infectiosum or aplastic crisis was quantitated. Sixty-five subjects in the acute phase of erythema infectiosum were involved, and in addition 22 serum samples from seven subjects with B19V-associated aplastic crisis complicating chronic hemolytic anemia were also analyzed. In the acute phase of erythema infectiosum the median B19V DNA load in the serum samples from the acute phase of erythema infectiosum was 7.63 × 105 genomes/ml, (range from 4.48 × 103 to 8.31 × 106 genomes/ml). The serum B19V DNA load during the acute phase of aplastic crisis complicating chronic hemolytic anemia was extremely high, that is 1010–1013 genomes/ml, and decreased gradually to around 105 genomes/ml over 1–2 months. Although all subjects followed an almost uniform and typical clinical course of erythema infectiosum, there was a large individual variation of B19V DNA loads, that is differences of over 1,000 times. Extremely high B19V loads were observed in subjects with aplastic crisis. This study is the first large scale report of studies of the B19V DNA loads in subjects with erythema infectiosum and aplastic crisis, the most common and significant clinical manifestations by B19V infections. J. Med. Virol. 86:2102–2106, 2014.
- 24 June 2014
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (12) , 2102-2106
Quantitation of human parvovirus B19 DNA in erythema infectiosum and aplastic crisis
Several publications concerning the methods of real-time PCR for human parvovirus B19 (B19V) have appeared and some case reports mention B19V DNA loads. However, no large-scale study quantitating levels of B19V DNA in common or representative B19V manifestations such as erythema infectiosum and aplastic crisis has been performed. Consequently, using the TaqMan PCR assay, the B19V load in a large sample of subjects with erythema infectiosum or aplastic crisis was quantitated. Sixty-five subjects in the acute phase of erythema infectiosum were involved, and in addition 22 serum samples from seven subjects with B19V-associated aplastic crisis complicating chronic hemolytic anemia were also analyzed. In the acute phase of erythema infectiosum the median B19V DNA load in the serum samples from the acute phase of erythema infectiosum was 7.63 × 105 genomes/ml, (range from 4.48 × 103 to 8.31 × 106 genomes/ml). The serum B19V DNA load during the acute phase of aplastic crisis complicating chronic hemolytic anemia was extremely high, that is 1010–1013 genomes/ml, and decreased gradually to around 105 genomes/ml over 1–2 months. Although all subjects followed an almost uniform and typical clinical course of erythema infectiosum, there was a large individual variation of B19V DNA loads, that is differences of over 1,000 times. Extremely high B19V loads were observed in subjects with aplastic crisis. This study is the first large scale report of studies of the B19V DNA loads in subjects with erythema infectiosum and aplastic crisis, the most common and significant clinical manifestations by B19V infections. J. Med. Virol. 86:2102–2106, 2014.
- 18 September 2013
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 29 (2) , 280-282
Acute Transverse Myelitis Associated With Human Parvovirus B19 Infection
We describe severe acute transverse myelitis in a previously healthy 9-year-old boy in whom primary human parvovirus B19 infection was confirmed serologically and B19 DNA was detected in his serum and cerebrospinal fluid. Besides erythema infectiosum, parvovirus B19 infection has various clinical manifestations; however, central nervous system involvement is rare. Even more unusual is parvovirus B19–associated acute transverse myelitis.
- 18 September 2013
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 29 (2) , 280-282
Acute Transverse Myelitis Associated With Human Parvovirus B19 Infection
We describe severe acute transverse myelitis in a previously healthy 9-year-old boy in whom primary human parvovirus B19 infection was confirmed serologically and B19 DNA was detected in his serum and cerebrospinal fluid. Besides erythema infectiosum, parvovirus B19 infection has various clinical manifestations; however, central nervous system involvement is rare. Even more unusual is parvovirus B19–associated acute transverse myelitis.